Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults

Claudio Ponticelli, Giorgio Graziani

Research output: Contribution to journalArticlepeer-review

Abstract

Idiopathic focal and segmental glomerular sclerosis is a frequent cause of nephrotic syndrome and end-stage renal disease. The pathogenesis is still unknown, although the body of evidence suggests that focal and segmental glomerular sclerosis is caused by a not clearly identified circulating factor that alters the permselectivity of the glomerular barrier. Proteinuria is followed by podocyte injury. Glucocorticoids, calcineurin inhibitors, cytotoxic agents and mycophenolate mofetil, either given alone or in combination, may obtain complete or partial remission of proteinuria in 50-60% of patients and protect them from end-stage renal disease, but the remaining patients are resistant to the available drugs. A number of new drugs, including rituximab, galactose and antifibrotic agents, are under investigation.

Original languageEnglish
Pages (from-to)251-261
Number of pages11
JournalExpert Review of Clinical Immunology
Volume9
Issue number3
DOIs
Publication statusPublished - 2013

Keywords

  • calcineurin inhibitors
  • focal glomerulosclerosis
  • glomerulonephritis
  • glucocorticoids
  • mycophenolate
  • nephrotic syndrome
  • rituximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults'. Together they form a unique fingerprint.

Cite this